Retifanlimab-Dlwr Becomes First and Only FDA-Approved First-Line Treatment for Advanced Anal Cancer

Source: Pharmacy Times articles

The FDA approves retifanlimab for advanced anal cancer, offering new hope with improved survival rates and treatment options for patients.
Read More